{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:39:28Z","timestamp":1778830768298,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.parkreldis.2015.09.021","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T06:33:34Z","timestamp":1441694014000},"page":"S37-S40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"S1","title":["New levodopa therapeutic strategies"],"prefix":"10.1016","volume":"22","author":[{"given":"Peter A.","family":"LeWitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2015.09.021_bib1","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","article-title":"Levodopa for the treatment of Parkinson's disease","volume":"359","author":"LeWitt","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib2","series-title":"Drugs for the Treatment of Parkinson's Disease","first-page":"325","article-title":"The pharmacology of levodopa in treatment of Parkinson disease: an update","volume":"vol. 88","author":"LeWitt","year":"1989"},{"issue":"Suppl 2","key":"10.1016\/j.parkreldis.2015.09.021_bib3","first-page":"S249","article-title":"A\u00a0brief history of levodopa","volume":"257","author":"Hornykiewicz","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2015.09.021_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism: chronic treatment with l-dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of levodopa","volume":"7","author":"Nutt","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update","volume":"45","author":"Nyholm","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.parkreldis.2011.03.014","article-title":"The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications","volume":"17","author":"Anderson","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0163-7258(02)00325-X","article-title":"L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system","volume":"97","author":"Misu","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib12","series-title":"Neurobiology of DOPA as a Neurotransmitter","first-page":"23","article-title":"DOPA as a neurotransmitter candidate","author":"Misu","year":"2006"},{"key":"10.1016\/j.parkreldis.2015.09.021_bib13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.lfs.2011.08.008","article-title":"L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease","volume":"89","author":"King","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib14","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1046\/j.1471-4159.1995.64041742.x","article-title":"Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin","volume":"64","author":"Newcomer","year":"1995","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.expneurol.2013.02.009","article-title":"Dual effects of L-DOPA on nigral dopaminergic neurons","volume":"247","author":"Guatteo","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jnr.23318","article-title":"5-S-cysteinyldopamine neurotoxicity: influence on the expression of \u03b1-synuclein and ERp57 in cellular and animal models of Parkinson's disease","volume":"92","author":"Aureli","year":"2014","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/mds.22587","article-title":"Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies","volume":"24","author":"LeWitt","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.514","volume":"55","author":"Hsu","year":"2015","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","article-title":"Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial","volume":"12","author":"Hauser","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/mds.26219","article-title":"Gastroretentive carbidopa\/levodopa, DM-1992, for the treatment of advanced Parkinson's disease","author":"Verhagen Metman","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e31824523de","article-title":"Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa\/carbidopa in patients with Parkinson disease","volume":"35","author":"Chen","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2015.09.021_bib23","first-page":"S248","article-title":"Accordion Pill carbidopa\/levodopa (AP CD\/LD) for treatment of advanced Parkinson's disease (PD)","volume":"29","author":"LeWitt","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.25742","article-title":"Double-blind study of an actively-transported levodopa prodrug, XP21279, in Parkinson disease","volume":"29","author":"LeWitt","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.09.021_bib25","first-page":"S99","article-title":"Inhaled levodopa (CVT-301) provides rapid improvement of OFF states in Parkinson's disease","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2015.09.021_bib26","first-page":"S87","article-title":"Pharmacokinetic profile of ND0612L (levodopa\/carbidopa) for subcutaneous infusion) in patients with moderate to severe Parkinson's disease","volume":"30","author":"Giladi","year":"2015","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380201500396X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380201500396X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T12:53:36Z","timestamp":1537361616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380201500396X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"alternative-id":["S135380201500396X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.021","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New levodopa therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}